Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Phase III Clinical Study Evaluating the Efficacy and Safety of Enlituo® Plus FOLFOX Versus Erbitux® Plus FOLFOX as First-line Treatment for Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.

NCT07595276 is registered in ClinicalTrials.gov with Taizhou Mabtech Pharmaceutical Co.,Ltd as lead sponsor.

NCT NCT07595276
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07595276 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Phase III Clinical Study Evaluating the Efficacy and Safety of Enlituo® Plus FOLFOX Versus Erbitux® Plus FOLFOX as First-line Treatment for Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.
Lead sponsor
Taizhou Mabtech Pharmaceutical Co.,Ltd
Phase
Phase 3
Overall status
Recruiting
Start date
May 27, 2026
Completion date
June 1, 2030
Enrollment
608 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer